If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-15. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
In addition, NMR was now being used to investigate and supplement crystal structures, as exemplified by the determination of an isolated tetraloop-receptor motif structure published in 1997. Investigations such as this enabled a more precise characterization of the base pairing and base stacking interactions which stabilized the global folds of large RNA molecules. The importance of understanding RNA tertiary structural motifs was prophetically well described by Michel and Costa in their publication identifying the tetraloop motif: "...it should not come as a surprise if self-folding RNA molecules were to make intensive use of only a relatively small set of tertiary motifs. Identifying these motifs would greatly aid modeling enterprises, which will remain essential as long as the crystallization of large RNAs remains a difficult task".
2024 United States elections 2024 United States gubernatorial elections 2024 United States House of Representatives elections 2024 United States Senate elections Timeline of the 2024 United States presidential election Republican Party efforts to disrupt the 2024 United States presidential election Fundraising in the 2024 United States presidential election
China's official military budget for 2025 was at 1.78 trillion yuan (US$246 billion), which is an increase of 7.2% over the last year. The Stockholm International Peace Research Institute (SIPRI) estimated that China's military expenditure was US$336 billion in 2025, the second-largest in the world after the United States and accounting for 12 percent of the world's defence expenditures.
Qi is a polysemous word that traditional Chinese medicine distinguishes as being able to transform into many different qualities of qi (气; 氣; qì). In a general sense, qi is something that is defined by five "cardinal functions":
Sources: en.wikipedia.org
Ciguatera fish poisoning (CFP), also known as ciguatera, is a foodborne illness caused by eating tropical reef fish contaminated with ciguatoxins. Such individual fish are said to be ciguatoxic. Symptoms may include diarrhea, vomiting, numbness, itchiness, dysesthesia, sensitivity to hot and cold, dizziness, and weakness with lethargy. The onset of symptoms varies with the amount of toxin absorbed. If a large quantity of toxins is consumed, symptoms may appear within half an hour. At lower amounts, symptoms may take a few days to appear. Diarrhea may last up to four days. Symptoms may last a few weeks to a few months. Heart problems such as slow heart rate and low blood pressure may occur. Shoemaker, House, and Ryan published a case definition of a chronic form of ciguatera poisoning that may develop: "Roughly 5% of these victims will develop chronic ciguatera (CC), a widespread, multisymptom, multisystem, chronic illness that can last tens of years." The specific toxins involved are ciguatoxins and maitotoxin. They are made by a small marine organism, Gambierdiscus toxicus, that grows on and around coral reefs in tropical and subtropical waters. These are eaten by herbivorous fish which in turn are eaten by larger carnivorous fish. The toxins become more concentrated as they move up the food chain. The fish most often implicated include barracuda, grouper, moray eel, amberjack, and sea bass. Diagnosis is based on a person's symptoms together with having recently eaten fish. If a number of those who eat the same fish develop symptoms the diagnosis becomes more likely.
=== Pharmacokinetics === Gepotidacin is rapidly absorbed orally, reaching peak plasma concentrations (tmax) after approximately 2.0 hours. In adults with uncomplicated urinary tract infections (uUTI) and normal renal function, the mean steady-state maximum concentration (Cmax) is 4.2 mcg/mL, and the area under the concentration-time curve over 12 hours AUC(0-12) is 22.8 mcg*hour/mL following a 1500 mg dose every 12 hours. Systemic exposure (Cmax and AUC) increases proportionally with dose. Accumulation of approximately 40% occurs and achieves a steady state by day 3. The absolute bioavailability is about 45%, and standard and moderate fat meals did not significantly affect its absorption. Gepotidacin's pharmacokinetics were found to be generally consistent across different ages, sexes, races, and body weights during modeling and simulation. Gepotidacin has a mean steady-state volume of distribution (Vss) of 172.9 liters and is 25-41% bound to plasma proteins. It has a terminal elimination half-life of approximately 9.3 hours and a total clearance of 33.4 L/hour. The primary metabolic pathway involves CYP3A4, with a minor metabolite (M4, ~11% of circulating drug). The co-administration of other drugs can influence gepotidacin levels. Strong inhibitors of CYP3A4 can increase gepotidacin exposure, whereas strong inducers of CYP3A4 can decrease it. Additionally, gepotidacin, at high concentrations, has shown the potential to increase the exposure of certain other drugs, including digoxin and midazolam.
The masseter a jaw muscle is claimed to be the strongest; the 1992 Guinness Book of Records records the achievement of a bite strength of 4,337 N (975 lbf) for 2 seconds. What distinguishes the masseter is its advantage in working against a much shorter lever arm than other muscles. Strength can refer to the force exerted by the muscle itself, such as where it inserts into a bone, then the strongest muscles are those with the largest cross-sectional area. This is because the tension exerted by an individual skeletal muscle fiber does not vary much. Each fiber can exert a force on the order of 0.3 micronewton. By this definition, the strongest muscle of the body can be said to be either the quadriceps femoris or the gluteus maximus. Because muscle strength is determined by cross-sectional area, a shorter muscle will be stronger by weight than a longer muscle of the same cross-sectional area. The myometrial layer of the uterus may be the strongest muscle by weight in the female body. At the time when an infant is delivered, the entire uterus weighs about 1.1 kg (40 oz). During childbirth, the uterus exerts 100 to 400 N (25 to 100 lbf) of downward force with each contraction. The external muscles of the eye are conspicuously large and strong in relation to the small size and weight of the eyeball, and are sometimes claimed to be a 100 times stronger than they need to be. Eye movements (particularly saccades used on facial scanning and reading) do require high speed movements, and eye muscles are exercised nightly during rapid eye movement sleep.
The healthy BMI range varies with the age and sex of the child. Obesity in children and adolescents is defined as a BMI greater than the 95th percentile. The reference data that these percentiles are based on is from 1963 to 1994 and thus has not been affected by the recent increases in rates of obesity. Childhood obesity has reached epidemic proportions in the 21st century, with rising rates in both the developed and the developing world. Rates of obesity in Canadian boys have increased from 11% in the 1980s to over 30% in the 1990s, while during this same time period rates increased from 4 to 14% in Brazilian children. In the UK, there were 60% more obese children in 2005 compared to 1989. In the US, the percentage of overweight and obese children increased to 16% in 2008, a 300% increase over the prior 30 years. As with obesity in adults, many factors contribute to the rising rates of childhood obesity. Changing diet and decreasing physical activity are believed to be the two most important causes for the recent increase in the incidence of child obesity. Advertising of unhealthy foods to children also contributes, as it increases their consumption of the product. Antibiotics in the first 6 months of life have been associated with excess weight at age seven to twelve years of age. Because childhood obesity often persists into adulthood and is associated with numerous chronic illnesses, children who are obese are often tested for hypertension, diabetes, hyperlipidemia, and fatty liver disease.
In the Earth's crust, the concentration of helium is 8 parts per billion. In seawater, the concentration is only 4 parts per trillion. There are also small amounts in mineral springs, volcanic gas, and meteoric iron. Because helium is trapped in the subsurface under conditions that also trap natural gas, the greatest natural concentrations of helium on the planet are found in natural gas, from which most commercial helium is extracted. The concentration varies in a broad range from a few ppm to more than 7% in a small gas field in San Juan County, New Mexico. As of 2021, the world's helium reserves were estimated at 31,000,000,000 cubic metres (1.1×1012 cu ft), with a third of that being in Qatar. In 2015 and 2016 additional probable reserves were announced to be under the Rocky Mountains in North America and in the East African Rift. The Bureau of Land Management (BLM) has proposed an October 2024 plan for managing natural resources in western Colorado. The plan involves closing 543,000 acres to oil and gas leasing while keeping 692,300 acres open. Among the open areas, 165,700 acres have been identified as suitable for helium recovery. The United States possesses an estimated 8.7×109 m3 (306,000,000,000 cu ft) of recoverable helium, sufficient to meet current consumption rates of 61,000,000 m3 (2,150,000,000 cu ft) per year for approximately 150 years.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.